Information Provided By: 
Fly News Breaks for August 13, 2019
OPTN
Aug 13, 2019 | 08:07 EDT
Jefferies analyst David Steinberg believes Optinose's first ever Xhance sales guidance of $29M-$34M for 2019 looks achievable based on the company's "solid" Q2 results and recent prescription trends. Further, $100M in full year 2020 Xhance sales does not seem like a stretch now, Steinberg tells investors in a post-earnings research note. With Optinose's fundamentals continuing to improve, there's increasingly a "disconnect" with the stock's valuation, says the analyst. He keeps a Buy rating on the shares with a $21 price target.
News For OPTN From the Last 2 Days
There are no results for your query OPTN
